400 related articles for article (PubMed ID: 31511599)
1. 21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes.
Tong Y; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
Sci Rep; 2019 Sep; 9(1):13123. PubMed ID: 31511599
[TBL] [Abstract][Full Text] [Related]
2. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
3. Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx
Kantor O; Barrera E; Kopkash K; Pesce C; Barrera E; Winchester DJ; Yao K
Ann Surg Oncol; 2019 Oct; 26(10):3232-3239. PubMed ID: 31342379
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
5. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
6. Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology.
Bello DM; Russell C; McCullough D; Tierno M; Morrow M
Ann Surg Oncol; 2018 Oct; 25(10):2884-2889. PubMed ID: 29968028
[TBL] [Abstract][Full Text] [Related]
7. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
8. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
Karsten M; Stempel M; Radosa J; Patil S; King TA
Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
[TBL] [Abstract][Full Text] [Related]
10. Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer.
Breaux A; Turner B; Wu X; Rai SN; Riley EC; Mandadi M; Sanders MA
Clin Breast Cancer; 2019 Feb; 19(1):e261-e269. PubMed ID: 30509870
[TBL] [Abstract][Full Text] [Related]
11. Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy.
Park KU; Chen Y; Chitale D; Choi S; Ali H; Nathanson SD; Bensenhaver J; Proctor E; Petersen L; Loutfi R; Simonds A; Kuklinski M; Doyle T; Dabak V; Cole K; Davis M; Newman L
Ann Surg Oncol; 2018 Jul; 25(7):1921-1927. PubMed ID: 29679201
[TBL] [Abstract][Full Text] [Related]
12. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
13. Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy.
Ju NR; Jeffe DB; Keune J; Aft R
Breast Cancer Res Treat; 2013 Jan; 137(1):195-201. PubMed ID: 23149464
[TBL] [Abstract][Full Text] [Related]
14. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
15. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
[TBL] [Abstract][Full Text] [Related]
17. Opposite Prognostic Impact of Single PTEN-loss and
Lazaridis G; Kotoula V; Vrettou E; Kostopoulos I; Manousou K; Papadopoulou K; Giannoulatou E; Bobos M; Sotiropoulou M; Pentheroudakis G; Efstratiou I; Papoudou-Bai A; Psyrri A; Christodoulou C; Gogas H; Koutras A; Timotheadou E; Pectasides D; Zagouri F; Fountzilas G
Cancer Genomics Proteomics; 2019; 16(3):195-206. PubMed ID: 31018950
[TBL] [Abstract][Full Text] [Related]
18. Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx.
Lee RM; Switchenko JM; Ho TB; Arciero CA; Bhave MA; Subhedar PD
Ann Surg Oncol; 2019 Oct; 26(10):3152-3158. PubMed ID: 31342377
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
[TBL] [Abstract][Full Text] [Related]
20. Breast Cancers of Special Histologic Subtypes Are Biologically Diverse.
Tadros AB; Wen HY; Morrow M
Ann Surg Oncol; 2018 Oct; 25(11):3158-3164. PubMed ID: 30094484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]